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Abstract
Introduction: The Livial Intervention Following Breast Cancer: Efficacy, Recurrence and Tolerability Endpoints
(LIBERATE: Clinical http://Trials.gov number NCT00408863), a randomized, placebo-controlled, double-blind trial that
demonstrated that tibolone (Livial), a tissue-selective hormone-replacement therapy (HRT), increased breast cancer
(BC) recurrence HR 1.40 (95% CI, 1.14 to 1.70; P = 0.001). A subgroup of women was entered into a study of bone
mineral density (BMD).
Methods: Women with surgically excised primary BC (T1-3, N0-2, M-0) within the last 5 years, complaining of
vasomotor symptoms, were assigned to tibolone, 2.5 mg daily, or placebo treatment for a maximum of 5 years. The
BMD substudy enrolled 763 patients, using dual-energy X-ray absorptiometry (DXA) scanning at baseline and at 2 years.
Results: In the bone substudy, 699 of 763 women were eligible (345 allocated to tibolone, and 354, to placebo).
After undergoing DXA scans, 300 (43%) women had normal BMD; 317 (45%), osteopenia; and 82 (11.7%),
osteoporosis. Low body-mass index (P < 0.001), Asian race (P < 0.001), and late age at menarche (P < 0.04)
predicted low bone mass at baseline. Tibolone increased BMD by 3.2% at the lumbar spine and 2.9% at the hip
compared with placebo (both P < 0.001). The majority of fractures (55%) occurred in osteopenic patients. Women
with normal BMD had increased recurrence with tibolone, 22 (15.6%) of 141 compared with placebo, 11 (6.9%) of
159 (P = 0.016), whereas no increased BC recurrence was seen in women with low BMD; 15 (7.4%) of 204 taking
tibolone versus 13 (6.7%) of 195 taking placebo.
Conclusions: Tibolone is contraindicated after BC treatment, as it increases BMD and BC recurrence. Risk of BC
recurrence was elevated in BC women with normal BMD (compared with low) who took tibolone.
Introduction
Osteoporosis (reduced bone mineral density (BMD))
leads to fractures that severely affect the quality of life
[1]. Postmenopausal women have increased bone loss
due to estrogen deficiency, resulting in an increased
fracture risk. Fracture risk also increases after a diagno-
sis of breast cancer [1,2]. Breast cancer (BC) patients
frequently have accelerated bone loss because of che-
motherapy, inducing premature menopause or
aromatase inhibitor (AI) therapy, lowering estrogen
levels, thus increasing fracture rate [3,4].
Although dual-energy X-ray absorptiometry (DXA) is
proposed to identify those with low BMD in women
commencing therapy, the incidence and frequency of
osteoporosis in BC patients has not been widely studied.
The bone substudies of the AI trials contained small
numbers of patients [5,6].
Tibolone (Livial) is a synthetic steroid with a pharmaco-
logic and clinical profile different from conventional sex
steroids; it reduces vasomotor symptoms and prevents
osteoporosis [7]. In the Longterm Intervention on Frac-
tures with Tibolone (LIFT) trial, tibolone, 1.25 mg/day,
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prevented spinal fractures in osteoporotic older women
compared with placebo, reducing the risk of BC (HR, 0.32;
0.13 to 0.80) [8]. Many women undergoing adjuvant ther-
apy for BC have vasomotor symptoms such as hot flushes;
both osteoporosis and vasomotor symptoms can poten-
tially be prevented by the use of tibolone.
The Livial Intervention Following Breast Cancer; Effi-
cacy, Recurrence and Tolerability Endpoints (LIBER-
ATE) study [9] set out to demonstrate noninferiority of
tibolone compared with placebo on BC recurrence, but
closed early because of increased BC recurrence with
tibolone.
Studies have suggested that normal BMD is associated
with an increased risk of BC development [10,11]. The
LIBERATE bone substudy, therefore, assessed the
changes in BMD with tibolone and determined the rela-
tion between the effects on BMD and BC recurrence in
this population.
Materials and methods
LIBERATE (http://ClinicalTrials.gov number
NCT00408863) was a randomized, placebo-controlled,
double-blind, parallel-group trial of tibolone (Livial), 2.5
mg/day, on BC recurrence, aiming to demonstrate the
noninferiority of treatment compared with placebo in
women with climacteric symptoms and a history of BC [9].
The primary end point was BC recurrence rate. Sec-
ondary study outcomes included vasomotor symptoms,
health-related quality of life (HRQL), overall survival,
and BMD. In total, 3,583 women were screened, of
whom 3,148 were randomized in 245 centers in 31
countries: 1,579 to tibolone and 1,569 to placebo [9].
The BMD substudy used DXA scanning at baseline
and after 2 years or at trial discontinuation, as long as
on trial medication. The aim was to explore the effect of
tibolone compared with placebo on BMD of the lumbar
vertebrae (L1 to L4) and left proximal femur for hip
density. Of 763 women randomized to the BMD sub-
study, only 699 had BMD assessed at any site: 697 at
the lumbar spine, and 691 at the hip, and entered the
study (Figure 1).
BMD was measured by using Lunar or Hologic instru-
ments. Bone densitometry data were acquired by DXA
technicians, trained by the Quality Control/Quality
Assurance (QC/QA) centers according to protocols pre-
pared by central QC/QA facilities. These facilities were
Figure 1 CONSORT diagram of participant flow.
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also responsible for continuous safety monitoring of
incoming data and for complete QC/QA procedures,
including cross-calibration of instruments at all clinical
trial sites, and data analysis. This ensured comparability
of the results over time and across different sites and
machines. If a scan of the left femur was not possible,
then the right femur could be used, and was used con-
sistently throughout the trial. DXA scans were per-
formed at baseline, after 2 years, or at trial
discontinuation, as long as the patient remained taking
the trial medication. Fractures were assessed by investi-
gators reporting their presence as a serious adverse
event.
Patients
Women with histologically confirmed BC (T1-3, N0-2,
M0), surgically treated within the last 5 years, irrespec-
tive of hormone-receptor status, were randomized
between July 2002 and December 2004. Patients were
younger than 75 years, with the last menstruation at
least 12 months before study start or ovariectomized,
hysterectomized, or taking gonadotropin-releasing hor-
mone (GnRH) analogues and with vasomotor symptoms,
either related to natural menopause or resulting from
prior or current adjuvant BC treatment. Use of tamoxi-
fen, aromatase inhibitors, GnRH analogues, or che-
motherapy was allowed. Recent or current use of
estrogenic or progesterogenic substances, as well as any
nonregistered investigational drug or Raloxifene hydro-
chloride, was not allowed. Bisphosphonates were not
allowed before study entry, and only 7% of women ever
used bisphosphonates in the LIBERATE trial. All
women gave informed consent, and the study was
approved by the Ethics Committees and/or Health
Authorities of the hospitals and countries involved.
Statistical analysis
All analyses were carried out for 699 women with a
BMD value at baseline in the intent-to-treat (ITT)
group. To deal with drop-outs, the observed case
approach was used. The following populations were
considered: overall population, Caucasian, and Asian
race.
According to the World Health Organization (WHO)
criteria, BMD was divided into three categories based
on the T-scores in the total hip: osteoporosis if T-score
in at least one site of 2.5 or less; osteopenia if T-score
in both sites was more than or equal to 2.5, and at least
for one site, the T-score was 1 or less; and normal if the
T-score in both sites was 1 or more [1].
For lumbar spine and total hip, multiple regression
analysis with forward stepwise selection was performed
to identify predicting factors for BMD at baseline as a
continuous variable. Prognostic factors were further
examined by fitting a logistic regression by using the
BMD classes osteoporotic and not normal (osteopenic
and osteoporotic) as response variables.
For each of the sites, change from baseline in BMD
and percentage change from baseline in BMD were ana-
lyzed by using an analysis of covariance (ANCOVA)
model with, as factors, Treatment group and Center,
and as covariate, the Baseline value. Additionally, both
binary outcomes, osteopenia and osteoporosis, were ana-
lyzed by using logistic regression models with, as factors,
Treatment group, Race, and as a covariate, BMI.
Differences in bone loss (defined as any decrease in
BMD from baseline) at both sites between tibolone and
placebo groups were analyzed by using the Pearson c2 test.
The occurrence of fractures was analyzed by using a
logistic regression model with, as factors, Treatment
group, Race (Caucasian versus Asian), Treatment by
race interaction, and BMD classes (osteoporotic versus
normal and osteopenic versus normal), and as covari-
ates, Age, Baseline body mass index (BMI), and Age at
menarche (and/or menopause).
Time to BC recurrence was analyzed by using a Cox
proportional hazards model, stratified by country, with
factors for Treatment and BMD classes and a covariate
for baseline BMI. A similar model is fitted with BMD
class (osteopenic and osteoporotic grouped into one
class) as a time-dependent factor to account for updated
BMD information during the first 2 years after
randomization.
To examine a linear trend with regard to the effect of
BMD classes on BC recurrence in the tibolone group
and the placebo group, similar models using BMD
classes as a continuous variable were fitted to each
treatment group separately, and the consistency of the
linear trend across the treatment groups was tested.
Role of funding source
An Independent International Steering Committee
advised on trial safety and conduct. The trial was funded
by Schering Plough.
Results
As previously reported, tibolone increased BC relapse
rates HR, 1.4 (95% CI, 1.14 to 1.70; P = 0.001), and the
trial closed prematurely [9].
Demographics and baseline characteristics of 699 sub-
jects who consented to the bone substudy and had a
BMD assessment at baseline (on or before day 1) of
either site are presented in Table 1 and Figure 1.
For both sites, (lumbar spine (LS) and hip), the tibo-
lone group showed an absolute increase in BMD after 2
years of treatment compared with an absolute decrease
in BMD seen with placebo (Figure 2/Additional file 1
Table S1: P < 0.001).
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Table 1 Demographics and other baseline characteristics of subjects with BMD data at baseline
Tibolone 2.5 mg (n = 345) Placebo (n = 354)
Osteoporosis
(n = 39)
Osteopenia
(n = 165)
Normal
(n = 141)
Osteoporosis
(n = 43)
Osteopenia
(n = 152)
Normal
(n = 159)
Age (years)
Mean (SD) 55.3 (7.3) 53.1 (7.3) 52.9 (7.4) 56.8 (7.2) 53.3 (7.0) 52.2 (6.4)
Median (range) 55.0 (43, 73) 53.0 (32, 74) 53.0 (34, 72) 57.0 (42, 70) 53.0 (36, 71) 52.0 (39, 75)
Body mass index (kg/m2)a N 36 164 138 43 151 158
Mean (SD) 24.0 (3.5) 25.1 (4.6) 26.5 (3.8) 24.3 (4.0) 25.1 (4.1) 27.7 (4.8)
Median (range) 23.9 (18, 33) 23.8 (17, 52) 25.7 (19, 37) 24.0 (19, 37) 23.9 (19, 39) 26.9 (19, 48)
Time since menopause (years)a N 35 143 116 39 135 134
Mean (SD) 10.5 (7.9) 6.9 (6.5) 7.3 (7.4) 8.4 (6.4) 7.1 (7.1) 5.0 (5.3)
Median (range) 8.4 (1, 35) 4.3 (0, 30) 4.6 (0, 31) 5.1 (0, 24) 4.3 (1, 30) 3.1 (0, 30)
Time since breast cancer surgery
(years)
N 39 165 141 43 152 159
Mean (SD) 2.4 (1.2) 2.2 (1.2) 2.2 (1.3) 2.4 (1.5) 2.3 (1.3) 2.0 (1.2)
Median (range) 2.3 (0, 5) 2.0 (0, 5) 2.1 (0, 5) 2.4 (0, 5) 2.1 (0, 5) 1.7 (0, 5)
Race n (%) Asian 26 (66.7) 76 (46.1) 31 (22.0) 26 (60.5) 63 (41.4) 38 (23.9)
Black 1 (0.7) 1 (0.6)
Caucasian 13 (33.3) 85 (51.5) 109 (77.3) 16 (37.2) 86 (56.6) 118 (74.2)
Other 4 (2.4) 1 (0.7) 1 (2.3) 2 (1.3) 2 (1.3)
Smoking at baseline n (%) No 39 (100.0) 144 (87.3) 122 (86.5) 38 (88.4) 133 (87.5) 137 (86.2)
Yes 21 (12.7) 19 (13.5) 5 (11.6) 19 (12.5) 22 (13.8)
Alcohol use at baseline n (%) No 36 (92.3) 111 (67.3) 78 (55.3) 32 (74.4) 96 (63.2) 83 (52.2)
Yes 3 (7.7) 54 (32.7) 63 (44.7) 11 (25.6) 56 (36.8) 76 (47.8)
Estrogen-receptor status n (%) Negative 12 (30.8) 36 (21.8) 21 (14.9) 12 (27.9) 49 (32.2) 30 (18.9)
Positive 27 (69.2) 122 (73.9) 116 (82.3) 29 (67.4) 101 (66.4) 126 (79.2)
Unknown 7 (4.2) 4 (2.8) 2 (4.7) 2 (1.3) 3 (1.9)
Progestagen-receptor status n (%) Negative 11 (28.2) 45 (27.3) 28 (19.9) 16 (37.2) 58 (38.2) 39 (24.5)
Positive 27 (69.2) 110 (66.7) 106 (75.2) 25 (58.1) 86 (56.6) 111 (69.8)
Unknown 1 (2.6) 10 (6.1) 7 (5.0) 2 (4.7) 8 (5.3) 9 (5.7)
Aromatase Inhibitora n (%) None 33 (84.6) 149 (90.3) 132 (93.6) 39 (90.7) 139 (91.4) 144 (90.6)
Ever, but not recent 1 (2.6) 3 (1.8) 1 (2.3) 4 (2.6) 2 (1.3)
Recent 5 (12.8) 13 (7.9) 9 (6.4) 3 (7.0) 9 (5.9) 13 (8.2)
Tamoxifena n (%) None 13 (33.3) 36 (21.8) 29 (20.6) 15 (34.9) 48 (31.6) 29 (18.2)
Ever, but not recent 4 (10.3) 16 (9.7) 9 (6.4) 1 (2.3) 10 (6.6) 14 (8.8)
Recent 22 (56.4) 113 (68.5) 103 (73.0) 27 (62.8) 94 (61.8) 116 (73.0)
GnRH analoguesa n (%) None 34 (87.2) 159 (96.4) 133 (94.3) 41 (95.3) 144 (94.7) 147 (92.5)
Ever, but not recent 1 (2.6) 1 (0.6) 2 (1.4) 1 (2.3) 3 (2.0) 1 (0.6)
Recent 4 (10.3) 5 (3.0) 6 (4.3) 1 (2.3) 5 (3.3) 11 (6.9)
Chemotherapya n (%) None 11 (28.2) 52 (31.5) 54 (38.3) 12 (27.9) 55 (36.2) 59 (37.1)
Ever, but not recent 25 (64.1) 109 (66.1) 83 (58.9) 28 (65.1) 94 (61.8) 96 (60.4)
Recent 3 (7.7) 4 (2.4) 4 (2.8) 3 (7.0) 3 (2.0) 4 (2.5)
Node status n (%) Missing 1 (0.7)
Negative 18 (46.2) 90 (54.5) 86 (61.0) 20 (46.5) 80 (52.6) 93 (58.5)
Positive 21 (53.8) 75 (45.5) 55 (39.0) 23 (53.5) 71 (46.7) 66 (41.5)
aStatistical analysis revealed no differences between groups for all of the above demographics and other baseline characteristics. Body mass index (P = 0.06) and
time since menopause (P = 0.06) were the only two continuous variables close to significance. Comparison between tibolone and placebo randomized patients
at baseline demonstrated no difference between groups for all of the demographics and other baseline characteristics. Body Mass Index (P = 0.06) and time
since menopause (P = 0.06) were the only two continuous variables that came close to significance.
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The percentage change from baseline for LS BMD and
total hip was 1.6% and 1.3%, respectively, in the tibolone
group, with a decrease of 1.6% at both sites observed
taking placebo (Figure 2 and Additional file 1 Table S1).
The percentage changes from baseline adjusted treat-
ment effects were 3.12 (95% CI, 2.41 to 3.84) and 2.85
(95% CI, 2.20 to 3.49) for the LS and total hip, respec-
tively. The Asian and Caucasian subgroups were simi-
lar at both the LS (P = 0.65) and total hip (P = 0.14).
Prediction of osteoporosis at baseline and at treatment
At baseline, 697 subjects had information on BMD of LS
(343 in the tibolone group versus 354 in the placebo
group), and 691 subjects had information on BMD of
the total hip (342 in the tibolone group versus 349 in
the placebo group). The majority of subjects were of
Asian (37.2%) or Caucasian (61.1%) races. Overall, 82
(11.7%) had osteoporosis in either hip or LS, 317
(45.4%) had osteopenia, and 300 (42.9%) had normal
BMD in both sites. Asian women (63.4%) contributed
the majority of women with osteoporosis, followed by
Caucasian women (35.4%). The osteopenia group con-
sisted of 53.9% Caucasians and 43.9% Asians. The
distribution of BMD categories based on T-score at
both sites was comparable among the treatment groups,
as were demographics and baseline characteristics
(Table 1) [12].
However, Asian women were more likely to be osteo-
porotic or osteopenic (P < 0.0001). Asian women had
lower weight and height (wt, 59.2 kg; ht, 156 cm) com-
pared with their Caucasian counterparts (wt, 71.5 kg; ht,
164 cm); both P < 0.0001.
After a stepwise selection procedure, Asian race, older
age, late age at menarche, longer time since breast sur-
gery, and low BMI were found to be significant (all P
values < 0.05) with regard to both total hip and LS T-
score at baseline (Table 2) and predicted nonnormal
BMD class (T-score 1 or less at both sites), as well as
osteoporosis (T-score, 2.5 or less) at baseline. Medical
oophorectomy by GnRH analogue use also predicted LS
but not total hip T-score at baseline (P = 0.039).
At baseline, 11.7% of subjects were osteoporotic, but
after 2 years of treatment, 15.4% in the placebo group
and 10.2% in the tibolone group remained osteoporotic.
In addition to osteoporosis at baseline, factors predicting
osteoporosis after 2 years were BMI (OR, 0.87; 95% CI,
 
 
Tibolone 1.6 (4.2) 1.4 (3.9) 1.9 (4.5) 1.3 (4.1) 1.3 (3.0) 1.2 (5.2) 
Placebo -1.6 (4.1) -1.5 (4.0) -1.8 (4.3) -1.6 (3.4) -1.3 (3.0) -2.0 (3.7) 
Figure 2 Bone mineral density change (%) from baseline after 2 years. Figure shows relative change from baseline of BMD (mean (SD)).
BMD changes on tibolone compared with placebo between baseline and 2 years of treatment. Tibolone significantly increased BMD, whereas
patients taking placebo had a 2% loss of BMD and had a lower weight and height. Overall, a 1.6% increase was found in BMD at lumbar spine
on tibolone and a 1.6% BMD loss on placebo, and similar magnitudes of change were seen at the hip (both P ≤ 0.01).
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0.78 to 0.98; P = 0.019), and treatment (tibolone versus
placebo, OR, 0.38; 95% CI, 0.16 to 0.88; P = 0.024). For
nonnormal BMD class, ethnicity was also an additional
risk factor (Asian race versus Caucasian race, OR, 3.02;
95% CI, 1.61 to 5.68; P = 0.0006).
For LS, the number of subjects who experienced bone
loss was 99 (37.2%) with tibolone versus 174 (66.4%)
with placebo (LS, P < 0.0001), whereas total hip-bone
loss occurred in 86 (32.0%) women taking tibolone ver-
sus 176 (66.9%) in the placebo group (P < 0.0001).
BMD and fractures
Thirty-eight fractures occurred, of which the majority,
21, occurred in the osteopenic group, 12 in the normal
BMD group, and only five in the osteoporotic group
(Table 3). Fractures occurred in 6.8% of osteopenic,
6.2% of osteoporotic, and 4.1% of normal-BMD women.
Logistic regression analysis, including age, BMI, age at
menarche and/or menopause, BMD classes at baseline,
treatment, race, and Treatment-by-Race interaction, and
race found no significant predictors of fracture (data not
shown). No significant effect of tibolone on fracture rate
was found, although in the Caucasian women, seven of
206 taking tibolone developed fractures compared with
17 of 221 taking placebo (c2, P = 0.054). Testing homo-
geneity of the tibolone-to-placebo odds ratios revealed
no difference between the Asian and Caucasian races, as
indicated by lack of Treatment-by-Race interaction.
Analysis of BC recurrence restricted to subjects with BMD
data
For subjects with BMD data, 61 women have experi-
enced a BC recurrence. Univariate analysis of the effect
of tibolone treatment on inducing BC recurrence
according to BMD at baseline, grouped as osteoporosis,
osteopenia, or normal, revealed recurrence with placebo
Table 2 Factors predicting bone mineral density (lumbar spine and total hip)
Numerator Denominator
End point Effect DF DF F value P value
Lumbar spine Race 2 665 26.19 < 0.0001
BMI 1 665 17.06 < 0.0001
Time since breast surgery (years) 1 665 7.74 0.006
AGE 1 665 6.32 0.012
Age at menarche (years) 1 665 4.74 0.030
Node status 1 665 4.77 0.029
GnRH analogues 2 665 3.26 0.039
Total hip Race 2 660 63.33 < 0.0001
BMI 1 660 149.15 < 0.0001
Time since breast surgery (years) 1 660 6.15 0.013
AGE 1 660 4.81 0.029
Factors predicting bone mineral density (BMD) at baseline. Asian women show significantly more osteoporosis (P ≤ 0.001) at both hip and lumbar spine. Older
age and lower BMI, both of which are recognized to predict BMD, were also significant.
Table 3 Fractures by BMD classification at baseline (on or before day 1), Asian and Caucasian
Tibolone 2.5 mg Placebo All
n Number of fractures % n Number of fractures % n Number of fractures %
Asian All 133 6 4.5 127 8 6.3 260 14 5.4
Osteoporosis 27 1 3.7 25 2 8.0 52 3 5.8
Osteopenia 75 4 5.3 64 5 7.8 139 9 6.5
Normal 31 1 3.2 38 1 2.6 69 2 2.9
Caucasian All 206 7 3.4 221 17 7.7 427 24 5.6
Osteoporosis 12 0 0.0 17 2 11.8 29 2 6.9
Osteopenia 85 4 4.7 86 8 9.3 171 12 7.0
Normal 109 3 2.8 118 7 5.9 227 10 4.4
All All 339 13 3.8 348 25 7.2 687 38 5.5
Osteoporosis 39 1 2.6 42 4 9.5 81 5 6.2
Osteopenia 160 8 5.0 150 13 8.7 310 21 6.8
Normal 140 4 2.9 156 8 5.1 296 12 4.1
No significant reduction in fractures occurred in the group overall, although an almost-significant reduction occurred in Caucasian patients taking tibolone (p =
0.054). Fractures according to baseline bone mineral density (BMD) classification: The percentage of women who developed bone fractures did not differ
between those with osteoporosis and osteopenia, but because osteopenia was the larger population group, more fractures occurred among osteopenic patients.
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was 4.7%, 7.2%, and 6.9%, respectively, whereas for tibo-
lone, it was 7.5%, 7.3%, and increased to 15.6% in
women with normal BMD (P = 0.03; Figure 3 and Addi-
tional file 2 Table S2).
Bisphosphonate use did not affect time to BC recur-
rence (HR, 0.82 (95% CI, 0.53 to 1.27)).
Results of fitting a proportional hazard Cox model
with Treatment, Osteopenia status, and Osteoporosis
status as factors and BMI as covariate indicate that tibo-
lone and normal BMD increased the BC recurrence
compared with placebo and osteopenia, respectively. Fit-
ting the same model for tibolone and placebo groups
separately suggested an increase in BC recurrence in
patients, with an increase in BMD seen in tibolone
group (HR = 0.47; 95% CI, 0.26 to 0.85; P = 0.017;
Additional file 3 Table S3) but not in the placebo group
(HR, 0.89; 95% CI, 0.47 to 1.68; P = 0.65), although test-
ing the homogeneity of the linear trend over BMD
classes indicated no differences between treatment
groups (P = 0.19).
Table 4 groups osteopenic and osteoporotic patients
together and uses this as a time-dependent covariate to
correct for changes in BMD during the course of the
first 2 years of the trial. The results indicate again that
tibolone and normal BMD are associated with increased
BC recurrence.
Discussion
Treatment of BC survivors with tibolone (a specific tis-
sue estrogenic-activity regulator) led to increases in
BMD and BC recurrence. Tibolone and other HRTs are
contraindicated after breast cancer treatment.
Recurrence with tibolone occurred mainly in women
with normal BMD. Osteoporosis increases with age, cur-
rent smoking, and low BMI [1,2,12]. The reduction of
estrogen levels increases BMD loss after the menopause
and increases the risk of fracture [2-6].
In BC survivors, adjuvant therapies increase bone loss,
leading to increased fractures and lower health-related
quality of life [2]. The prevalence of osteoporosis has
been reported to be up to 27% in BC survivors [11];
11.7% of women recruited to the LIBERATE bone sub-
study were osteoporotic, and 45.4%, osteopenic, despite
being only an average of 2.2 years since diagnosis.
The higher incidence of low BMD measurements
(compared with the general population) and increased
fracture rate observed in women after a diagnosis of BC
[2] has resulted in ASCO and European Guidelines sug-
gesting that all women diagnosed with BC should
 Tib Plac Tib Plac Tib Plac 
n 39 43 165 152 141 159 
BC 
Recurrence 
3 
(7.7%) 
2 (4.7%) 12 
(7.3%) 
11 
(7.2%) 
22 
(15.6%) 
11 (6.9%) 
Figure 3 Baseline bone mineral density (BMD) and breast cancer recurrence. Incidence of breast cancer recurrence with tibolone or
placebo according to baseline BMD. Significantly more breast cancers occurred in women with normal BMD taking tibolone (15.6%) compared
with either osteopenic or osteoporotic patients (7.3% and 7.7%, respectively; P ≤ 0.016).
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undergo DXA scanning to detect those women at risk of
fracture [7] and to initiate treatment at an early stage if
osteoporosis is indicated by the DXA results.
BMD scanning identifies women with BC at risk of
fragility fracture, but 55% of fractures occurred in the
osteopenic group compared with 13% among the “high
risk” osteoporotic women (Table 3), indicating that
BMD alone cannot be used to select patients for antire-
sorptive therapy to prevent fragility fracture. Few (6.5%)
patients in this study were taking AI, but the fracture
rate (2.8% per annum) remains comparable with that
reported in patients taking AIs in randomized trials
[3-6]. Treatment with intravenous zoledronic acid, 4
mg/day, has been shown to increase BMD in pre- and
postmenopausal women with breast cancer [13], and
recent results from the ABCSG-12/ZO-FAST trials sug-
gest that when combined with endocrine therapy, this
combination improved disease-free recurrence compared
with endocrine therapy alone, but the Zoledronic Acid
Adjuvant Therapy (AZURE) trial results did not confirm
a disease-recurrence benefit. However, bisphosphonates
(not hormone-replacement therapies) should be used in
BC survivors with low BMD [13-15].
Current American Society of Clinical Oncology and
UK guidelines recommend bisphosphonate therapy for
women with a T score of 2.0 or more. To prevent the
majority of fractures would require all women with T
scores greater than -1.0 to undergo antiresorptive ther-
apy [7]. An alternative approach in osteopenic women
with BC advocates commencing antiresorptive therapy
in women with one other recognized risk factor for frac-
ture, such as history of fragility fracture, BMI < 20, cor-
ticosteroid use, or a cigarette-smoking habit [16].
BMD is a function of the lifetime exposure of a
woman to estrogen [12,17]. In the LIBERATE study,
osteoporosis was associated with older age, lower BMI,
late age at menarche, and Asian race. Important racial
differences in BMD exist, with lower BMD in the Asian
race compared with Caucasians. The application of Cau-
casian reference values to an Asian population may not
reflect the true osteoporosis rate and fracture risk in
Asians [17,18]. After adjusting for other factors, such as
height and weight, the BMD and bone mass are
reported not to differ between Asians and Caucasians
[19]. However, trabecular BMD decreases at an earlier
age in Asian women, and the fracture threshold (espe-
cially spinal fracture) is lower [20]. Fracture rates in the
Asian population were comparable to those of Cauca-
sians, indicating that a low BMD in Asian women is
predictive of fracture risk.
In the LIFT trial, tibolone reduced fractures in osteo-
porotic women [8], and in the LIBERATE Caucasian
population, tibolone increased BMD and reduced frac-
ture risk (OR = 0.42; P = 0.06). Tibolone increased
BMD regardless of ethnic background.
Breast cancer risk
BC risk is associated with a high lifetime exposure to
estrogen, and BMD may be a surrogate marker for this
exposure. Studies have shown an association between
higher BMD and increased risk of BC [11-13,15]. The
Women’s Health Initiative study indicated that hip
BMD predicted BC risk independent of Gail score [21].
The contribution of BMD in the prediction of postme-
nopausal BC score was significant in a Cox proportional
hazards model and independent of the Gail score. Nor-
mal BMD appears to be associated with an increased
BC risk [22].
In the Multiple Outcomes of Raloxifene Evaluation
(MORE) trial, women with low bone mass (T-score, 2
or less) had a higher incidence of invasive, estrogen
receptor-positive BC than did those with osteoporosis
(HR, 2.13; 95% CI, 1.12 to 4.03). Raloxifene, an anties-
trogen, reduced the incidence of BC development in this
group [11]. In the LIFT trial, tibolone (1.25 mg/day)
likewise reduced BC risk in a population of osteoporotic
women [8].
In the LIBERATE study, which used tibolone, 2.5 mg/
day, in women after BC treatment, the incidence of BC
recurrence increased. Recurrence was highest in the
group with normal BMD randomized to tibolone com-
pared with those with low BMD. In the placebo group,
an increase in BC recurrence was seen in the normal
and osteopenic women, compared with osteoporotic
Table 4 Analysis of variance table for breast cancer recurrence
Parameter Estimate Std error Χ2 DF P value Hazard ratio 95%
Confidence limits
Tibolone 0.50 0.26 3.75 1 0.05 1.64 0.99, 2.72
BMI -0.01 0.03 0.07 1 0.79 0.99 0.93, 1.06
Osteopenia
(T-score ≤ -1)
-0.57 0.27 4.41 1 0.04 0.57 0.34, 0.96
These results are restricted to subjects with any BMD assessment, using a proportional hazard Cox model with Treatment, Osteopenia (defined as T-score ≤ -1) as
time-dependent factors and Body mass index (BMI) as covariate. For those patients with baseline and either 2-year or second BMD measurements at trial end, an
analysis was carried out to correct for changes in BMD on treatment. Osteopenic and osteoporotic patients were grouped together to take account of changes in
BMD during the course of the trial. Tibolone use in women with normal BMD values was associated with increased breast cancer recurrence with a Hazard Ratio
that reached significance.
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women. The finding that normal BMD is associated
with increased BC recurrence provides support to the
concept that normal BMD is a surrogate for postmeno-
pausal estrogen levels or that women with normal BMD
are more sensitive to estrogenic stimulation. BMD may
be a biomarker of drug effect, so that as BMD gain
occurred with tibolone, BC risk increased (Table 4).
This is similar to the reduced BC risk seen in the
MORE Trial, with increased BMD gain with the anties-
trogen raloxifene. Alternatively, women with higher
BMD may harbor single-nucleotide polymorphisms
(SNPs) of the estrogen-receptor alpha or CYP 17/19
genes, which result in higher ER alpha at similar estro-
gen levels and reduce the risk of developing early osteo-
porosis and fracture [23]. Follow-up of women with
known BMD and ER SNPs should allow this possibility
to be explored.
Conclusions
Women with normal bone density not only have a
higher lifetime exposure to estrogen but also have a
lower threshold for estrogen stimulation of BMD
increases and BC recrudescence. The placebo groups in
studies protecting against AI-induced bone loss by using
bisphosphonates will allow confirmation (or not) that
low BMD is associated with a low risk of BC recurrence.
Tibolone and other HRTs should not be used as
osteoporosis treatment in women with breast cancer, as
they increase the risk of recurrence.
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